Abo, Y.-N., Jamrozik, E., McCarthy, J. S., Roestenberg, M., Steer, A. C., & Osowicki, J. (2023). Strategic and scientific contributions of human challenge trials for vaccine development: Facts versus fantasy. The Lancet Infectious Diseases, 23(12), e533–e546. https://www.thelancet.com/action/showPdf?pii=S1473-3099%2823%2900294-3
Adams, R. M., & Gonik, B. (2024). The Evolving Maternal Vaccine Platform. Reproductive Medicine, 5(3), 154–171. https://doi.org/10.3390/reprodmed5030014
Agarwal, N., Gupta, N., Dutta, T., Mahajan, M., & HS, S. (2024). Typhoid Conjugate Vaccine: A Boon for Endemic Regions. Cureus, 16(3). https://www.cureus.com/articles/211374-typhoid-conjugate-vaccine-a-boon-for-endemic-regions.pdf
Andrews, J. R., Baker, S., Marks, F., Alsan, M., Garrett, D., Gellin, B. G., Saha, S. K., Qamar, F. N., Yousafzai, M. T., & Bogoch, I. I. (2019). Typhoid conjugate vaccines: A new tool in the fight against antimicrobial resistance. The Lancet Infectious Diseases, 19(1), e26–e30. (NOT OA)
Antillón, M., Bilcke, J., Paltiel, A. D., & Pitzer, V. E. (2017). Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low-and middle-income settings. Vaccine, 35(27), 3506–3514.https://doi.org/10.1016/j.vaccine.2017.05.001
BATOOL, R. Impact Assessment of Typhoid Conjugate Vaccine in South Asian Slums. https://trepo.tuni.fi/bitstream/handle/10024/224785/978-952-03-3847-3.pdf?sequence=2
Batool, R., Qamar, Z. H., Salam, R. A., Yousafzai, M. T., Ashorn, P., & Qamar, F. N. (2024). Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: A systematic review and meta-analysis. The Lancet Global Health, 12(4), e589–e598. https://www.thelancet.com/action/showPdf?pii=S2214-109X%2823%2900606-X
Berlanda Scorza, F., Martin, L. B., Podda, A., & Rappuoli, R. (2022). A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development. Human Vaccines & Immunotherapeutics, 18(6), 2136451.
Birkhold, M., Mwisongo, A., Pollard, A. J., & Neuzil, K. M. (2021). Typhoid conjugate vaccines: Advancing the research and public health agendas. The Journal of Infectious Diseases, 224(Supplement_7), S781–S787. https://doi.org/10.1080/21645515.2022.2136451
Capeding, M. R., Sil, A., Tadesse, B. T., Saluja, T., Teshome, S., Alberto, E., Kim, D. R., Park, E. L., Park, J. Y., & Yang, J. S. (2020). Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind study. EClinicalMedicine, 27. https://www.thelancet.com/action/showPdf?pii=S2589-5370%2820%2930284-4
Capeding, M. R., Teshome, S., Saluja, T., Syed, K. A., Kim, D. R., Park, J. Y., Yang, J. S., Kim, Y. H., Park, J., & Jo, S.-K. (2018). Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children. Vaccine, 36(26), 3794–3801. https://doi.org/10.1016/j.vaccine.2018.05.038
Carey, M. E., McCann, N. S., & Gibani, M. M. (2022). Typhoid fever control in the 21st century: Where are we now? Current Opinion in Infectious Diseases, 35(5), 424–430. DOI: 10.1097/QCO.0000000000000879
Chakraborty, S., & Das, S. (2024). Typhoid & paratyphoid vaccine development in the laboratory: A review & in-country experience. The Indian Journal of Medical Research, 160(3–4), 379. doi: 10.25259/IJMR_1382_2024
Deen, J., & Clemens, J. D. (2022). Vaccine clinical trials in low-and middle-income countries: A brief review of standard, newer and proposed approaches. Expert Review of Vaccines, 21(11), 1595–1602.https://doi.org/10.1080/14760584.2022.2126357
Frost, I., Sati, H., Garcia-Vello, P., Hasso-Agopsowicz, M., Lienhardt, C., Gigante, V., & Beyer, P. (2023). The role of bacterial vaccines in the fight against antimicrobial resistance: An analysis of the preclinical and clinical development pipeline. The Lancet Microbe, 4(2), e113–e125. https://www.thelancet.com/action/showPdf?pii=S2666-5247%2822%2900303-2
Gibani, M. M., Britto, C., & Pollard, A. J. (2018). Typhoid and paratyphoid fever: A call to action. Current Opinion in Infectious Diseases, 31(5), 440–448. DOI: 10.1097/QCO.0000000000000479
Giersing, B. K., Isbrucker, R., Kaslow, D. C., Cavaleri, M., Baylor, N., Maiga, D., Pavlinac, P. B., Riddle, M. S., Kang, G., & MacLennan, C. A. (2023). Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries. The Lancet Global Health, 11(11), e1819–e1826. https://www.thelancet.com/action/showPdf?pii=S2214-109X%2823%2900421-7
Hasso-Agopsowicz, M., Sparrow, E., Cameron, A. M., Sati, H., Srikantiah, P., Gottlieb, S., Bentsi-Enchill, A., Le Doare, K., Hamel, M., & Giersing, B. K. (2024). The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens. Vaccine. https://doi.org/10.1016/j.vaccine.2024.06.017
Hausdorff, W. P., Madhi, S. A., Kang, G., Kaboré, L., Bayona, M. T., & Giersing, B. K. (2024). Facilitating the development of urgently required combination vaccines. The Lancet Global Health, 12(6), e1059–e1067. https://www.thelancet.com/action/showPdf?pii=S2214-109X%2824%2900092-5
Hoffman, S. A., LeBoa, C., Date, K., Haldar, P., Harvey, P., Shimpi, R., An, Q., Zhang, C., Jayaprasad, N., & Horng, L. (2023). Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India. Clinical Infectious Diseases, 77(1), 138–144. https://doi.org/10.1093/cid/ciad132
Jin, C., Gibani, M. M., Moore, M., Juel, H. B., Jones, E., Meiring, J., Harris, V., Gardner, J., Nebykova, A., & Kerridge, S. A. (2017). Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: A randomised controlled, phase 2b trial. The Lancet, 390(10111), 2472–2480. https://www.thelancet.com/action/showPdf?pii=S0140-6736%2817%2932149-9
Kajal, Pandey, A., & Mishra, S. (2024). From ancient remedies to modern miracles: Tracing the evolution of vaccines and their impact on public health. 3 Biotech, 14(10), 242. DOI: 10.1007/s13205-024-04075-7 (NOT OA)
Khan, M. I., Franco-Paredes, C., Sahastrabuddhe, S., Ochiai, R. L., Mogasale, V., & Gessner, B. D. (2017). Barriers to typhoid fever vaccine access in endemic countries. Research and Reports in Tropical Medicine, 37–44.https://www.tandfonline.com/doi/epdf/10.2147/RRTM.S97309?needAccess=true
Kulkarni, P. S., Potey, A. V., Bharati, S., Kunhihitlu, A., Narasimha, B., Yallapa, S., ... & Sahoo, S. (2024). The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial. The Lancet, 403(10436), 1554-1562. (NOT OA)
Laurens, M. B., Sirima, S. B., Rotrosen, E. T., Siribie, M., Tiono, A., Ouedraogo, A., Liang, Y., Jamka, L. P., Kotloff, K. L., & Neuzil, K. M. (2019). A phase II, randomized, double-blind, controlled safety and immunogenicity trial of typhoid conjugate vaccine in children under 2 years of age in Ouagadougou, Burkina Faso: A methods paper. Clinical Infectious Diseases, 68(Supplement_2), S59–S66. https://doi.org/10.1093/cid/ciy1104
Longley, A. T., Date, K., Luby, S. P., Bhatnagar, P., Bentsi-Enchill, A. D., Goyal, V., Shimpi, R., Katkar, A., Yewale, V., & Jayaprasad, N. (2021). Evaluation of vaccine safety after the first public sector introduction of typhoid conjugate vaccine—Navi Mumbai, India, 2018. Clinical Infectious Diseases, 73(4), e927–e933.https://doi.org/10.1093/cid/ciab059
Martin, L. B., Tack, B., Marchello, C. S., Sikorski, M. J., Owusu-Dabo, E., Nyirenda, T., Mogasale, V., & Crump, J. A. (2024). Vaccine value profile for invasive non-typhoidal Salmonella disease. Vaccine, 42(19), S101–S124. https://doi.org/10.1016/j.vaccine.2024.04.045
Meiring, J. E., Laurens, M. B., Patel, P., Patel, P., Misiri, T., Simiyu, K., Mwakiseghile, F., Tracy, J. K., Masesa, C., & Liang, Y. (2019). Typhoid Vaccine Acceleration Consortium Malawi: A phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi. Clinical Infectious Diseases, 68(Supplement_2), S50–S58. https://doi.org/10.1093/cid/ciy1103
Meiring, J. E., Patel, P., Patel, P., & Gordon, M. A. (2018). Typhoid conjugate vaccines: Making vaccine history in Africa. Expert Review of Vaccines, 17(8), 673–676. https://doi.org/10.1080/14760584.2018.1496825
Mohan, V. K., Varanasi, V., Singh, A., Pasetti, M. F., Levine, M. M., Venkatesan, R., & Ella, K. M. (2015). Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: A multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clinical Infectious Diseases, 61(3), 393–402. https://doi.org/10.1093/cid/civ295
Nampota-Nkomba, N., Carey, M. E., Jamka, L. P., Fecteau, N., & Neuzil, K. M. (2023). Using typhoid conjugate vaccines to prevent disease, promote health equity, and counter drug-resistant typhoid fever. 10(Supplement_1), S6–S12.https://doi.org/10.1093/ofid/ofad022
Nampota-Nkomba, N., Nyirenda, O. M., Datta, S., Mapemba, V., Patel, P. D., Misiri, T., Mwakiseghile, F., Ndaferankhande, J. M., Lipenga, B., & Oshinsky, J. (2025). Immunogenicity and reactogenicity of a booster dose of a typhoid conjugate vaccine (TCV) in Malawian pre-school children. eClinicalMedicine, 81.https://www.thelancet.com/action/showPdf?pii=S2589-5370%2825%2900032-X
Nampota-Nkomba, N., Nyirenda, O. M., Khonde, L., Mapemba, V., Mbewe, M., Ndaferankhande, J. M., Msuku, H., Masesa, C., Misiri, T., & Mwakiseghile, F. (2022). Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: A nested substudy of a double-blind, randomised controlled trial. The Lancet Global Health, 10(9), e1326–e1335.https://www.thelancet.com/action/showPdf?pii=S2214-109X%2822%2900275-3
Nassimbwa Kabanda, D. (n.d.). Malaria and Typhoid Fever Infection Rates in Pregnant Women: A Comprehensive Review.https://www.researchgate.net/profile/Kampala-International-University
O’Reilly, P. J., Pant, D., Shakya, M., Basnyat, B., & Pollard, A. J. (2020). Progress in the overall understanding of typhoid fever: Implications for vaccine development. Expert Review of Vaccines, 19(4), 367–382. ttps://doi.org/10.1080/14760584.2020.1750375
Patel, P. D., Liang, Y., Meiring, J. E., Chasweka, N., Patel, P., Misiri, T., Mwakiseghile, F., Wachepa, R., Banda, H. C., & Shumba, F. (2024). Efficacy of typhoid conjugate vaccine: Final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. The Lancet, 403(10425), 459–468.https://www.thelancet.com/action/showPdf?pii=S0140-6736%2823%2902031-7
Patel, P. D., Patel, P., Liang, Y., Meiring, J. E., Misiri, T., Mwakiseghile, F., Tracy, J. K., Masesa, C., Msuku, H., & Banda, D. (2021). Safety and efficacy of a typhoid conjugate vaccine in Malawian children. New England Journal of Medicine, 385(12), 1104–1115.DOI: 10.1056/NEJMoa2035916
Perera, S. R., Sokaribo, A. S., & White, A. P. (2021). Polysaccharide vaccines: A perspective on non-typhoidal Salmonella. Polysaccharides, 2(3), 691–714. https://doi.org/10.3390/polysaccharides2030042
Qamar, F. N., Qureshi, S., Haq, Z., Yousafzai, T., Qazi, I., Irfan, S., Iqbal, N., Amalik, Z., Hotwani, A., & Ali, Q. (2024). Longevity of immune response after a single dose of typhoid conjugate vaccine against Salmonella Typhi among children in Hyderabad, Pakistan. International Journal of Infectious Diseases, 147, 107187. https://doi.org/10.1016/j.ijid.2024.107187
Riddle, M., Chen, W., Kirkwood, C., & MacLennan, C. (2018). Update on vaccines for enteric pathogens. Clinical Microbiology and Infection, 24(10), 1039–1045.https://doi.org/10.1016/j.cmi.2018.06.023
Shakya, M., & Pollard, A. J. (2024). Typhoid conjugate vaccines: a step towards typhoid control. The Lancet Global Health, 12(4), e535-e536.https://www.thelancet.com/action/showPdf?pii=S2214-109X%2824%2900055-X
Shakya, M., Colin-Jones, R., Theiss-Nyland, K., Voysey, M., Pant, D., Smith, N., Liu, X., Tonks, S., Mazur, O., & Farooq, Y. G. (2019). Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. New England Journal of Medicine, 381(23), 2209–2218. DOI: 10.1056/NEJMoa1905047
Sirima, S. B., Ouedraogo, A., Barry, N., Siribie, M., Tiono, A., Nébié, I., Konaté, A., Berges, G. D., Diarra, A., & Ouedraogo, M. (2021). Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. International Journal of Infectious Diseases, 108, 465–472.https://doi.org/10.1016/j.ijid.2021.05.061
Steele, A. D., Hay Burgess, D. C., Diaz, Z., Carey, M. E., & Zaidi, A. K. (2016). Challenges and opportunities for typhoid fever control: A call for coordinated action. Clinical Infectious Diseases, 62(suppl_1), S4–S8.https://doi.org/10.1093/cid/civ976
Tadesse, B. T., Cardona, R. S. B., & Marks, F. (2024). Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?. The Lancet, 403(10425), 413-415. (NOT OA)
Vashishtha, V. M., & Kalra, A. (2020). The need & the issues related to new-generation typhoid conjugate vaccines in India. Indian Journal of Medical Research, 151(1), 22–34. DOI: 10.4103/ijmr.IJMR_1890_17
Vashishtha, V. M., & Kumar, P. (2024). The durability of vaccine-induced protection: An overview. Expert Review of Vaccines, 23(1), 389–408. https://doi.org/10.1080/14760584.2024.2331065
Vashishtha, V. M., & Kumar, P. (2025). Typhoid conjugate vaccines: Is a single dose enough for durable protection? Expert Review of Vaccines, just-accepted. https://doi.org/10.1080/14760584.2025.2476525
Voysey, M., & Pollard, A. J. (2018). Seroefficacy of Vi polysaccharide–tetanus toxoid typhoid conjugate vaccine (Typbar TCV). Clinical Infectious Diseases, 67(1), 18–24.https://doi.org/10.1093/cid/cix1145
Bhattacharyya, A., & Shahabuddin, S. M. (2024). Adult vaccination in India: A rapid review of current status & implementation challenges. The Indian Journal of Medical Research, 160(3-4), 279. doi: 10.25259/IJMR_1521_2024
Birkhold, M., Mwisongo, A., Pollard, A. J., & Neuzil, K. M. (2021). Typhoid conjugate vaccines: advancing the research and public health agendas. The Journal of Infectious Diseases, 224(Supplement_7), S781-S787. https://doi.org/10.1093/infdis/jiab449
Kundu, R., Kandulna, A. K., Nayak, U., Jangid, S. K., Babu, T. R., Vukkala, R., ... & Patel, P. (2020). Immunogenicity and safety of typhoid conjugate vaccine in healthy Indian subjects: a randomized, active-controlled, comparative clinical trial. Indian Pediatrics, 57, 625-630. (NOT OA)
Lightowler, M. S., Manangazira, P., Nackers, F., Van Herp, M., Phiri, I., Kuwenyi, K., ... & Luquero, F. J. (2022). Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: a matched case control study. Vaccine, 40(31), 4199-4210. https://doi.org/10.1016/j.vaccine.2022.04.093
Meiring, J. E., Laurens, M. B., Patel, P., Patel, P., Misiri, T., Simiyu, K., ... & Neuzil, K. M. (2019). Typhoid Vaccine Acceleration Consortium Malawi: a phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi. Clinical Infectious Diseases, 68(Supplement_2), S50-S58. https://doi.org/10.1093/cid/ciy1103
Mohan, V. K., Varanasi, V., Singh, A., Pasetti, M. F., Levine, M. M., Venkatesan, R., & Ella, K. M. (2015). Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clinical Infectious Diseases, 61(3), 393-402. https://doi.org/10.1093/cid/civ295
Nampota-Nkomba, N., Nyirenda, O. M., Khonde, L., Mapemba, V., Mbewe, M., Ndaferankhande, J. M., ... & Laurens, M. B. (2022). Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. The Lancet Global Health, 10(9), e1326-e1335. https://www.thelancet.com/action/showPdf?pii=S2214-109X%2822%2900275-3
Patel, P. D., Patel, P., Liang, Y., Meiring, J. E., Misiri, T., Mwakiseghile, F., ... & Neuzil, K. M. (2021). Safety and efficacy of a typhoid conjugate vaccine in Malawian children. New England Journal of Medicine, 385(12), 1104-1115. DOI: 10.1056/NEJMoa2035916
Shakya, M., Voysey, M., Theiss-Nyland, K., Colin-Jones, R., Pant, D., Adhikari, A., ... & Pollard, A. J. (2021). Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. The Lancet Global Health, 9(11), e1561-e1568. https://www.thelancet.com/action/showPdf?pii=S2214-109X%2821%2900346-6